Perioperative Outcomes and Pathological Response After Neoadjuvant Nivolumab Plus Platinum Chemotherapy in Clinically Node-Negative Non-Small Cell Lung Cancer.

Takuya Watanabe Kotaro Nomura Shinkichi Takamori S. Tane S. Ohara H. Oiki Shinya Katsumata Makoto Endo Satoshi Takamori M. Nakatsuka H. Tenpaku R. Nakamura H. Notsuda K. Namba K. Minegishi Masayuki Tanahashi Masahiro Tsuboi J. Soh M. Shimokawa Y. Ohde

Sep 2026 · Annals of Surgical Oncology · 0 citations · 13 references

Medicine

TL;DR

In patients with resectable cN0 NSCLC, nivolumab-based neoadjuvant chemoimmunotherapy was associated with perioperative outcomes and pCR rates similar to those observed in patients with cN1-2, suggesting that this regimen may represent a treatment option for patients with cN0, with careful attention to irAEs and disease progression.

DOI PubMed Semantic Scholar

View source

Similar papers

Oct 2026

Impact of Neoadjuvant Immunotherapy Combined with Chemotherapy on Surgical Margin Strategy in Central Non-Small-Cell Lung Cancer.

Lian-Min Zhang, Yi-Jie Wang, Xiao-Fei Wang et al. · Annals of Surgical Oncology · 0 citations

Oct 2026

Primary feasibility analysis of neoadjuvant chemotherapy with bevacizumab for resectable stage II/IIIA non-squamous non-small cell lung cancer: the NAVAL phase II study.

N. Tsubokawa, Yasuhiro Tsutani, Y. Miyata et al. · Japanese Journal of Clinical... · 0 citations

Review Open access Oct 2026

Efficacy and safety of neoadjuvant chemoimmunotherapy for locally advanced oral squamous cell carcinoma: a two-center real-world retrospective cohort study.

Neoadjuvant chemoimmunotherapy is increasingly being explored for resectable, locally advanced oral squamous cell carcinoma, and yet real-world evidence regarding its effectiveness and safety remains limited. In addition, a proportion of patients do not proceed to surgery after neoadjuvant treatment, and outcomes in th...

Huan-Gan Liao, Jun-Wei Zhang, Yun-Jie Wang et al. · Journal of cranio-maxillo-fa... · 0 citations

Open access Aug 2026

Induction chemo-immunotherapy followed by surgery or radiotherapy for locally-advanced III stage non-small cell lung cancer: prospective single center non-randomized study (preliminary results)

Background. The evolving modalities of systemic treatment for non-small cell lung cancer (NSCLC) promotes the need to redefine different strategies for combined treatment in stage III and borderline-resectable lung cancer. Hereby we present the outcomes of a neoadjuvant chemo-immunotherapy regimen with subsequent in...

Y. Esakov, O. A. Kuchevskaya, I. Pokataev et al. · Malignant tumours · 0 citations

Sep 2026

The efficacy and feasibility of neoadjuvant immunochemotherapy versus chemotherapy in Limited-Stage Small-Cell lung cancer.

BACKGROUND The efficacy of neoadjuvant immunochemotherapy (NIC) in limited-stage small-cell lung cancer (LS-SCLC) remains undefined. This study aimed to evaluate the pathological and survival outcomes of NIC versus neoadjuvant chemotherapy (NC) and to compare NIC with upfront surgery in a real-world setting. MATERIAL...

Yun-Chu Wei, Ruo-Yi Jin, Xu Liu et al. · Lung Cancer · 0 citations

Open access Oct 2026

Role of postoperative radiotherapy in locally advanced esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy: A retrospective propensity score-matched study

Although neoadjuvant immunochemotherapy (NCIT) has shown promising prospects in the treatment of locally advanced esophageal squamous cell carcinoma (LA-ESCC), the role of adjuvant radiotherapy in these patients remains unclear. This study aimed to investigate the impact of postoperative adjuvant radiotherap...

Li Li, X. Jing, Ming-Juan Sun et al. · Therapeutic Advances in Medi... · 0 citations